ClinicalTrials.gg
TerminatedNCT03780725Updated Jan 13, 2026Results posted

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

A Phase 1 interventional study of BI 754111 and [89Zr]Zr-BI 754111 in Carcinoma, Non-Small-Cell Lung and Head and Neck Neoplasms, sponsored by Boehringer Ingelheim. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Boehringer Ingelheim.

Enrollment
47th of 49
8 · median 44
Started
2019
with 1 other
Phase 1
21 of 68
1 open now
Registered
58th of 68
by date

Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 47th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2019, is one of 21 in phase 1, and was the 58th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The main objective of this study is to determine the biodistribution and intra-tumor accumulation of [89Zr]Zr-BI 754111 at baseline and its change upon treatment

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Head and Neck Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written Form (ICF) prior to any trial specific procedures, sampling, or analyses
  • Patients of legal age (according to local legislation) at the time of signature of the ICF
  • Patients with confirmed diagnosis of recurrent NSCLC who received anti- or anti PD-L1 as Part of last treatment with at least 3 months of stable disease (i.e.patients with confirmed response (PR or CR) regardless of duration of response or stable disease (SD) for a minimum of 3 months) and have become to anti-PD- 1/ anti-PD-L1 based treatment OR

    --Patients with histologically confirmed diagnosis of recurrent HNSCC who progressed after platinum based therapy or not indicated for receiving standard (radio) chemotherapy (previous treatment with anti- PD-1/ PD-L1 is allowed)

  • (ECOG, R01-0787) score: 0 to 1
  • Patient must have at least one PET imageable and evaluable tumor lesion of 20mm
  • Patients must have at least one tumor lesion amenable to . This lesion should be PET imageable and evaluable as defined above and the biopsy should be obtained before first BI 754091 administration, unless medically . In the latter case, 25 4μm sections from an archival biopsy taken at relapse after the previous treatment are acceptable
  • Must have evaluable lesion(s) according to Revised (RECIST) Version 1.1 and
  • of at least 12 weeks after the start of the treatment according to the Investigator's judgement
  • Male or female patients. Women of (WOCBP)1 and men able to father a child must be ready and able to use highly effective methods of per International Conference on Harmonisation (ICH) M3 (R2) (that result in a low failure rate of less than 1% per year when used consistently and correctly) during trial Participation and for at least 6 months after the last administration of trial medication. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion criteria

Exclusion Criteria:

  • Not having fully recovered from major surgery before they enter into the trial according to investigator judgment or planned for major surgery within 12 months after screening, e.g. hip replacement
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled
  • Previous treatment in this trial
  • Any or anti-tumor treatment within 4 weeks or within 5 half-life periods (whichever is shorter) prior to the initiation of trial treatment.
  • Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 neuropathy due to prior platinum-based therapy
  • Prior treatment with anti-LAG-3 agents
  • Presence of other active invasive cancers other than the one treated in this trial, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment
  • Untreated (es) that may be considered active. Patients with previously treated brain metastases may Participate provided they are stable (i.e., without evidence of PD by imaging for at least 4 weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline), and there is no evidence of new or enlarging brain metastases
  • Inadequate organ function or bone marrow reserve as demonstrated by the laboratory values
  • Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec
    • Any abnormalities in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
    • \<55% or the lower limit of normal of the institutional standard.
  • History of pneumonitis within the last 5 years
  • History of severe reactions to other mAbs
  • doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study treatment.
  • Active disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy
  • Active infection requiring systemic treatment (antibacterial, antiviral, or antifungal therapy) at start of treatment in this trial
  • Known history of infection or an active or C virus infection
  • Interstitial lung disease
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes him/her an unreliable trial patient or unlikely to complete the trial or unable to comply with the protocol procedures
  • Women who are pregnant, nursing, or who plan to become pregnant in the trial
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Part 1: Ezabenlimab 240mg + BI 754111 600mg

    Drug: BI 754111 · Drug: [89Zr]Zr-BI 754111 · Drug: BI 754091

  • Experimental
    Part 2: Ezabenlimab 240mg + BI 754111 40mg

    Drug: BI 754111 · Drug: [89Zr]Zr-BI 754111 · Drug: BI 754091

Interventions

  • DrugBI 754111

    Solution for infusion

  • Solution for infusion

  • Solution for infusion

    Also known as: Ezabenlimab

06

What researchers measure

Primary outcomes

  1. Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 1

    The standardized uptake values (SUVs) are calculated as the ratios of the image derived radioactivity concentration upon the whole body concentration of the injected radioactivity, i.e. image derived radioactivity concentration / injected radioactivity concentration upon the whole body - a unitless value since the unit has been cancelled out. The Standard uptake value (SUV) in a 1 milliliter (mL) sphere around highest SUV pixel (SUVpeak) of \[89Zr\]Zr-BI 754111 for tumor uptake for part 1 participants is reported. The SUVpeak (also unitless since it is a SUV value) is summarized for each imaging time point (96hour, 144hour) as the mean tumor uptake over all selected lesions for each treatment cycle, respectively.

    Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.

  2. Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 2

    The standardized uptake values (SUVs) are calculated as the ratios of the image derived radioactivity concentration upon the whole body concentration of the injected radioactivity, i.e. image derived radioactivity concentration / injected radioactivity concentration upon the whole body - a unitless value since the unit has been cancelled out. The Standard uptake value (SUV) in a 1 milliliter (mL) sphere around highest SUV pixel (SUVpeak) of \[89Zr\]Zr-BI 754111 for tumor uptake for part 2 participants is reported. The SUVpeak (also unitless since it is a SUV value) is summarized for each imaging time point (96hour, 144hour) as the mean tumor uptake over all selected lesions for each treatment cycle, respectively.

    Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.

07

Results

Posted Jan 13, 2026

Participant flow

This was an open label Positron Emission Tomography (PET) imaging study to investigate the bio-distribution and tumor uptake of \[89Zr\]Zr-BI 754111 in patients with advanced non-small cell lung cancer and head and neck squamous cell carcinoma treated with BI 754111 in combination with BI 754091.

Participant flow — Overall Study
MilestonePart 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mg
Started35
Treated with at least one dose of ezabenlimab and bi 75411134
Completed00
Not completed35
Withdrew: Progression of disease34
Withdrew: Adverse event01

Outcome measures

PrimaryStandard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 1

The standardized uptake values (SUVs) are calculated as the ratios of the image derived radioactivity concentration upon the whole body concentration of the injected radioactivity, i.e. image derived radioactivity concentration / injected radioactivity concentration upon the whole body - a unitless value since the unit has been cancelled out. The Standard uptake value (SUV) in a 1 milliliter (mL) sphere around highest SUV pixel (SUVpeak) of \[89Zr\]Zr-BI 754111 for tumor uptake for part 1 participants is reported. The SUVpeak (also unitless since it is a SUV value) is summarized for each imaging time point (96hour, 144hour) as the mean tumor uptake over all selected lesions for each treatment cycle, respectively.

Time frame:
At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.
Reported as:
Mean · SUV ratio
Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 1
SUV ratioPart 1: Ezabenlimab 240mg + BI 754111 600mg
Cycle 1 (baseline phase) - 96 hours5.5 ± 1.0
Cycle 1 (baseline phase) - 144 hours5.2 ± 1.0
Cycle 2 (on-treatment phase) - 96 hours6.2 ± 2.7
Cycle 2 (on-treatment phase) - 144 hours7.0 ± 3.6
Statistical analysis
  • Part 1: Ezabenlimab 240mg + BI 754111 600mg · Mean relative change from baseline: 17.1Mean relative change from baseline (Cycle 1) to on treatment (Cycle 2) is reported.
PrimaryStandard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 2

The standardized uptake values (SUVs) are calculated as the ratios of the image derived radioactivity concentration upon the whole body concentration of the injected radioactivity, i.e. image derived radioactivity concentration / injected radioactivity concentration upon the whole body - a unitless value since the unit has been cancelled out. The Standard uptake value (SUV) in a 1 milliliter (mL) sphere around highest SUV pixel (SUVpeak) of \[89Zr\]Zr-BI 754111 for tumor uptake for part 2 participants is reported. The SUVpeak (also unitless since it is a SUV value) is summarized for each imaging time point (96hour, 144hour) as the mean tumor uptake over all selected lesions for each treatment cycle, respectively.

Time frame:
At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.
Reported as:
Mean · SUV ratio
Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 2
SUV ratioPart 2: Ezabenlimab 240mg + BI 754111 40mg
Cycle 1 (baseline phase) - 96 hours5.8 ± 4.4
Cycle 2 (on-treatment phase) - 96 hours4.6 ± 1.9
Cycle 1 (baseline phase) - 144 hours4.9 ± 3.6
Cycle 2 (on-treatment phase) - 144 hours4.3 ± 2.0
Statistical analysis
  • Part 2: Ezabenlimab 240mg + BI 754111 40mg · Mean relative change from baseline: -5.9Mean relative change from baseline (Cycle 1) to on treatment (Cycle 2) is reported.

Adverse events

Collected over From first dose of study medication until end of treatment + 30 days, up to 255 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Ezabenlimab 240mg + BI 754111 600mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Part 2: Ezabenlimab 240mg + BI 754111 40mg0/5 (0%)2/5 (40%)4/5 (80%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPart 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mg
PyrexiaGeneral disorders0/32/5
MalaiseGeneral disorders1/31/5
Infectious pleural effusionInfections and infestations1/30/5
Medical device site infectionInfections and infestations1/30/5
Respiratory tract infectionInfections and infestations1/30/5
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/5
Microcytic anaemiaBlood and lymphatic system disorders1/30/5
Gastric haemorrhageGastrointestinal disorders1/30/5
Device malfunctionProduct issues1/30/5
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/30/5
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPart 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mg
Muscle spasmsMusculoskeletal and connective tissue disorders2/30/5
Decreased appetiteMetabolism and nutrition disorders2/30/5
AnaemiaBlood and lymphatic system disorders2/30/5
DiarrhoeaGastrointestinal disorders1/31/5
Abdominal pain upperGastrointestinal disorders1/30/5
Food poisoningGastrointestinal disorders1/30/5
OesophagitisGastrointestinal disorders1/30/5
DizzinessNervous system disorders1/30/5
Musculoskeletal painMusculoskeletal and connective tissue disorders1/31/5
ArthralgiaMusculoskeletal and connective tissue disorders1/30/5

Baseline characteristics

Treated Set (TS) : This patient set includes all patients who were documented to have received at least one dose of \[89Zr\]Zr-BI 754111, BI 754111, or BI 754091 (ezabenlimab).

Age, Continuous
Age, Continuous(Years)Part 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mgTotal
Mean65.3 ± 9.064.6 ± 8.664.9 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mgTotal
Female011
Male347
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mgTotal
Hispanic or Latino000
Not Hispanic or Latino358
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Ezabenlimab 240mg + BI 754111 600mgPart 2: Ezabenlimab 240mg + BI 754111 40mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White358
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Amsterdam UMC Locatie VUMC
    Amsterdam, 1081HV, Netherlands
09

References and documents

Publications

  • Miedema IHC, Huisman MC, Zwezerijnen GJC, Grempler R, Pitarch AP, Thiele A, Hesse R, Elgadi M, Peltzer A, Vugts DJ, van Dongen GAMS, de Gruijl TD, Menke-van der Houven van Oordt CW, Bahce I. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2068-2080. doi: 10.1007/s00259-023-06164-w. Epub 2023 Mar 2. PubMed 36859619 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2020, 12 months.

Results were first posted in Jan 2026, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Dec 19, 2018
StartActual
Jan 22, 2019
Primary completionActual
Feb 19, 2020
CompletionActual
Dec 8, 2020
Results first posted
Jan 13, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03780725
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Jan 22, 2019
Primary completion
Feb 19, 2020
Completion
Dec 8, 2020
Results posted
Jan 13, 2026
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezabenlimab

Start the discussion